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INTRODUCTION 
 
          Hypertensive disorders complicate 5-10 % of all pregnancies. 
Preeclampsia is identified in 3.9 % of all pregnancies1  (Williams 23rd ). 
          It forms one of the deadly triad, along with hemorrhage and 
infection. They contribute greatly to maternal mortality rate.                
          In developed countries 16% of maternal deaths were due to 
hypertensive disorders2.  In India around 18- 15%  of maternal deaths were 
due to hypertensive disorders. Importantly half of these deaths were 
preventable3. 
           Preeclampsia is a pregnancy specific syndrome related to vasospasm 
and endothelilal damage. Where in the patient returns back to normal 
following delivery. 
      Preeclampsia is hypertension with protienuria after 20 weeks of 
gestation in women with previously normal blood pressure which returns to 
normal within 12 weeks gestation4. 
          Mild Preeclampsia is   defined   as hypertension associated with 
proteinuria, greater than 0.3 g/L in a 24-hour urine collection or 1+ by 
qualitative urine examination two times 6 hours apart, after 20 weeks of 
gestation5 . 
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            Proteinuria is defined as 24 hour urinary protein excretion 
exceeding 300 mg, a urine protein: creatinine ratio of ≥ 0.3, or persistent 
30 mg / dl (1+) in dipstick two times 6 hours apart. 
           Diagnosis of gestational hypertension is made in women whose 
systolic blood pressure reaches 140 mm of hg and above or when diastolic 
blood pressure reaches 90 mm hg and above, for the first time after 20 
weeks gestation, without  protienuria . The blood pressure returns to 
normal by 12 weeks postpartum6. 
              Abnormal laboratory findings in tests of renal, hepatic and 
hematological function increase the certainty of preeclampsia. 
                Preeclampsia often affects young and nulliparous women. The 
incidence is markedly influenced by race, ethnicity and has genetic 
predisposition. Other risk factors include obesity , multifetal gestation, 
thrombophilias. 
          Taking into consideration the various devastating complications 
of preeclampsia such as abruption, eclampsia, HELLP syndrome, 
cerebrovascular accidents and various neonatal complications, the need to 
curtail this disease from progressing is evident. 
           Hence we are committed to identify pregnant women with 
preeclampsia , manage them and thereby prevent adverse maternal and 
fetal outcome.   
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           In India the most commonly used antihypertensives in 
pregnancy are methyl dopa, labetalol and nifedipine. Previously the most 
commonly used drug was methyl dopa.  Now a days methyl dopa has 
been largely replaced by T.Labetalol and T.Nifedipine, due to its slower 
onset of action. 
           Both T.Labetalol and T.Nifedipine  are rapid in onset and 
effective  in the treatment of hypertension. They  have minimal maternal 
and fetal side effects.  
            Hence  this study is to compare the anti hypertensive efficacy 
of T.Labetalol and  T.Nifedipine in  mild preeclampsia. The  feto 
maternal outcome were also studied. 
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AIMS AND OBJECTIVES 
 
To compare the anti hypertensive efficacy of T. Labetalol with                
T. Nifedipine in mild preeclampsia. 
To study the maternal and perinatal outcome in mild preeclampsia 
following treatment with T.Labetalol or T. Nifedipine. 
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                                     INCLUSION CRITERIA 
  All antenatal women with mild preeclampsia . 
                                     EXCLUSION CRITERIA 
 Gestational hypertension 
 Severe preeclampsia 
 Eclampsia 
 Chronic hypertension 
 Associated  co morbidities - heart disease, diabetes mellitus, 
bronchial asthma,  gestational diabetes mellitus, renal disease. 
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MATERIALS AND METHODS 
          The study was conducted at the Government Raja Mirasudar Hospital, 
Thanjavur from October 2012 to October 2013 . 
          100 antenatal women with mild preeclampsia were selected. Informed 
consent obtained. 50 women were treated with T.Labetalol. 50 women were 
treated with T.Nifedipine. 
          Thorough  history and clinical examination were done. Once the 
diagnosis of mild preeclampsia was made, all patients were admitted. 
Investigations such as complete blood count, peripheral smear, blood sugar, 
liver function test, renal function test, prothrombin time, clotting time, 
bleeding time, fundus examination of eye, ultrasound abdomen were done. 
           Patients with blood pressure 150/100 mm of Hg and above were 
started on antihypertensive drug (NICE Guidelines 2011). In Group A, 50 
patients were treated with T.Labetalol.In Group B, 50 patients were treated 
with T. Nifedipine.  
          Serial monitoring of blood pressure was done. Antihypertensive 
efficacy and feto maternal outcomes were monitored. 
              Control aimed to keep systolic BP <150 mm Hg and diastolic 
between 80-100 mm Hg (NICE Guidelines, UK- 2011). 
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           In Group A, T.Labetalol was started with a dose of 100 mg .Blood 
pressure was measured 2nd   hourly and  the dose was increased by 100 mg 
every 6th  hourly until adequate control was achieved. The next day the total 
dose required was divided and given as twice daily dosage. The same dose 
was continued thereafter from the 2nd day of treatment. Then blood 
pressure was measured four times a day. 
            In Group B, T.Nifedipine was started at dose of 10 mg, blood 
pressure was measured 2nd  hourly, dose increased by 10mg  6th   hourly 
until adequate control was achieved. Total dose was divided as thrice daily 
dosage from the 2nd day. The same dose continued there after. Blood 
pressure was measured four times a day. 
       Patients were enquired about imminent symptoms,body weight  and 
urine albumin were checked every day. Antenatal  Steroids were given to 
patients with gestational age between 28 to 34 weeks for fetal lung maturity.                
        Patients were counselled well about the complications and the need for 
good compliance. In patients with  gestational age was less than 37 weeks,                                 
 once adequate control was achieved and if the patient is compliant for 
follow up, patients were discharged.            
        Patients were followed up in antenatal OPD every week by measuring 
blood pressure and repeating all investigations. Patients were warned about 
imminent symptoms and were asked to report immediately. 
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           Pregnancy was terminated at 37 weeks gestation. Patients who 
developed severe preeclampsia were  terminated. Patients diagnosed for the 
first time after 37 weeks gestation were also terminated. 
          Antihypertensive efficacy , disease progression, gestational age at 
delivery, drug side effects and neo natal complications were documented. 
           Immediately following delivery blood pressure was measured every 2 
hours for 24 hours. There after BP was measured four times a day. The 
antihypertensive was continued if BP was ≥ 150/100 mm Hg .       
            Patients were discharged on the 5th postnatal day if BP was under 
control. Patients who were on antihypertensive during the postnatal period 
were advised to continue the drug till 12 weeks postpartum and then tapered 
according to their blood pressure. 
          Patients were helped to make their choice about contraception. 
          Patients were followed up every week in postpartum centre until 12 
weeks postpartum. 
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REVIEW OF LITERATURE 
  
           Incidence of  hypertensive disorders of pregnancy is 5-10%. It is the 
most common condition where an otherwise healty parturient can become 
critically ill. The classical triad of preeclampsia is hypertension, proteinuria 
and edema. 
Risk factors of pre eclampsia7: 
Age:  <20 years,  > 35 years 
Primi gravida 
Genetic predisposition 
Obesity 
Multifetal gestation  
 Lower Socioeconomic status 
Preeclampsia in previous pregnancy 
Factor V  laiden mutation deficiency 
Pre existing medical diseases like chronic hypertension, renal disease, 
IDDM, Thrombophilias 
Polyhydramnios 
Hydrops foetalis 
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Etiology of Preeclampsia : 
Abnormal trophoblastic invasion of uterine vessels. 
Immunological dysregulation 
Endothelial cell dysfunction due to oxidative stress. 
Genetic polymorphism 
 
                          PATHOGENESIS OF PREECLAMPSIA8 
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Normal Pregnancy 
↓   Vasoconstriction 
↓   Platelet aggregation 
↓    Uterine activity 
↑   Uteroplacental bloodflow 
↑   Vasoconstriction 
↑   Platelet aggregation 
↑   Uterine activity 
↓    Uteroplacental bloodflow 
Prostacyclin Thromboxane 
Endoperoxide 
Arachidonic acid 
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                                          PRE ECALAMPSIA9
↓   Vasoconstriction 
↓   Platelet aggregation 
↓    Uterine activity 
↑   Uteroplacental bloodflow 
↑   Vasoconstriction 
↑   Platelet aggregation 
↑   Uterine activity 
↓    Uteroplacental bloodflow Prostacyclin 
Thromboxane 
Endoperoxide 
Arachidonic acid 
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Pathological changes in Preeclampsia10: 
Brain: 
 Cerebral perfusion pressure plays an important role in preeclampsia. 
Vascular  barotraumas and loss of cerebral vascular autoregulation 
leading to cerebral edema. 
   Liver: 
  Initially vasodilation of arterioles causing dislocation and degeneration 
of hepatocytes. Later intense vasospasm leading to infarction and 
necrosis. The incidence  of haemorrhage is 60% and necrosis is 40% in 
eclampsia women. 50% of preeclamptic women have hepatic damages. 
 Kidney11: 
a.  Glomerular changes: The primary pathology is in endothelial cells 
which are increased in size and there by occlude the capillary 
endotheliosis. There is broadening of the basement membrane. 
Podocytes are normal. 
b. Non Glomerular changes: Proximal renal tubules are dialated with 
tubular necrosis and juxta glomerular apparatus enlargement. Hyaline 
and fat deposition in tubules. 
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Vascular changes in preeclampsia12: 
 
 
            The spiral arteries in the myometrium does not undergo the normal 
pregnancy changes, that is increase in diameter due to vascular reaction to 
the trophoblast. They undergo acute atherosis, progressing to vessel 
obliteration and placental infarction. 
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 Placental changes or hypoxic reperfusion injury causes hypoxic 
damage to cytotrophoblasts  that leads to apoptosis and necrosis13. Figure14 
 
Pathophysiological changes in preeclampsia: 
Cardiovascular changes15: 
             The cardiovascular disturbance in preeclampsia is due to: 
1. Increased cardiac afterload due to vasospasm. 
2. Pathologically decreased hypervolemia of pregnancy which 
affects the preload of the heart. 
3. Endothelial cell activation leading to extravasation of 
intravascular fluid into extracellular space. 
4. Decreased cardiac output as a result of increased peripheral 
resistance. 
5. Hyperdynamic ventricular function and elevated pulmonary 
capillary wedge pressure. 
               These changes along with alveolar endothelial- epithelial leak 
compounded by decreased oncotic pressure favours pulmonary oedema in 
preeclampsia. 
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Blood volume: 
               The hallmark of preeclampsia is hemoconcentration due to 
vasoconstriction and endothelial leakage of plasma. Thus women with 
preeclampsia are unduly sensitive to fluid therapy and normal blood loss at 
delivery. 
Blood and Coagulation16: 
Thrombocytopenia:  
Platelet count of < 100000 cells/cu mm indicates a severe disease 
where in the pregnancy has to be terminated, as it usually worsens. Platelet 
count becomes normal within 3 to 5 days of delivery. 
Other changes include platelet degranulation, Thromboxane A2   
release, platelet surface attraction leading to platelet aggregation. 
Coagulation17: 
Increased factor VII consumption, decreased antithrombin III, 
increased protein C & S leading to hypercoagulable state. Fibronectin is 
elevated in preeclampsia. 
Endocrine changes: 
In preeclampsia Atrial Natriuretic Peptide is increased. 
Fluid and Electrolytes: 
           Due to endothelial injury there is pathological fluid retention in 
the extracellular fluid leading to edema. 
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Renal System: 
        The renal perfusion and glomerular filtration is reduced. This is 
due to the fivefold increase in renal afferent arteriolar resistance. The 
plasma uric acid is increased due to decreased glomerular filteration and 
increased tubular absorption. 
Proteinuria18: 
          The threshold is <300 mg / 24 hour quantitative urine 
specimen. It corresponds to <30 mg / dl or trace  in dipstick random 
specimen.  A urine protein creatinine ratio of  ≥ 0.3 indicates significant 
proteinuria. In preeclampsia it is nonselective proteinuria with abundant and 
coarse granular casts. 
Acute renal failure: 
Acute tubular necrosis and irreversible cortical necrosis are rarely 
associated with preeclampsia. 
Hepatic System19: 
     The destructive lesions are Periportal haemorrhage, hematoma and 
hepatic infarction usually associated with HELLP syndrome. Women with 
preeclampsia complicated by HELLP syndrome have worse prognosis. 
Central Nervous System: 
      The classical lesions include fibrinoid necrosis of arterioles, 
perivascular microinfarcts and haemorrhages. 60%  of eclamptic women 
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have gross intracerebral haemorrhage. Other lesions include cortical, 
subcortical edema and periventricular  haemorrhage. 
Classification of Hypertensive disorders of pregnancy: 
            Gestational Hypertension 
            Preeclampsia: Mild & Severe 
            Eclampsia 
           Chronic Hypertension            
           Chronic Hypertension with super imposed preeclampsia. 
 
FACTORS  DIFFERENTIATING  MILD FROM SEVERE         
 PREECLAMPSIA20: 
 MILD SEVERE 
Systolic BP <160mm hg >/160mm hg 
Diastolic BP <110mm hg >110mm hg 
Urinary protein 1+ or 2+ 3+ or 4+ 
Urine output >500ml/hr <500ml/hr 
Epigastric pain No Yes 
Head ache No Yes 
Visual disturbance No Yes 
Pulmonary edema No Yes 
HELLP syndrome No Yes 
Right hypochondrial pain No Yes 
Platelet count >100,000  
Cells/ cu mm 
<100,000 
Cells/ cu mm  
 
 27
Genetics in preeclampsia: 
          Preeclampsia loci sharing significant linkage are 2p12, 2p 25,  9p13 . 
Genetic imprinting with susceptibility locus on 10 q 22  is confirmed to be   
associated with preeclampsia21. 
         MTHFR( 1p36.3) , F5 (Laiden 1q23), AGT(1q42),  HLA(6p21), ACE          
( 17q23) are  the genes associated with preeclampsia syndrome22. 
 
Prevention of preeclampsia23: 
                  Supplementation with calcium, zinc, magnesium, protein, 
vitamin E and C. 
                  Fish ,  Evening primrose oil  
                  Low salt diet, Diuretics,  Antihypertensives 
           All these stratergies have been evaluated in many randomized trials  
but none has been proved to be clinically efficacious (Sibai et al. 2009).    
           The use of low dose aspirin has to be individualized due to its 
marginal benefits in delaying the onset of preeclampsia24 (CLASP Trial). 
 
Biophysical tests for prediction of preeclampsia25: 
Uterine artery doppler 
Roll over test  
Angiotensin  II  injection test  
Isometric exercise 
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Mid pregnancy Mean Arterial Pressure  
Increased maternal serum uric acid 
 These tests are sensitive in the prediction of preeclampsia but not 
specific. 
  Best available test is uterine artery doppler . The presence of 
persistent diastolic notching at18- 22 weeks . It is 96% specific and 
76% sensitive in predicting preeclampsia. 
Circulating markers of oxidative stress in preeclampsia26  
 MDA levels 1000- 5000 times higher in women with preeclampsia.  
  KTP (carboxy terminal telopeptide of type 1 collagen) 
 PICP (carboxy terminal polypeptide of type 1 collagen) 
 Markers of  bone reabsorption and bone formation are greater in 
women with preeclampsia. 
 Increased second trimester MSAFP/beta HCG  
 Decreased urinary calcium excretion.  
 Higher fasting insulin levels 
 Hyper triglyceridemia 
 Fibronectins 
 Hyperhomocysteinemia 
 Fetal free Deoxy ribo Nucleic Acid 
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 These markers of oxidative stress have been evaluated but they have 
limited value in the prediction of preeclampsia. 
 
Maternal complications of preeclampsia: 
                   HELLP Syndrome 
                   Eclampsia 
                   Disseminated intravascular coagulation   
                  Abruptio placenta 
                  Acute renal failure 
                  Ascites 
                  Pulmonary edema 
                  Pleural effusion 
                  Cerebral edema 
                  Retinal detachment 
                  Laryngeal edema 
                  Subscapular liver haematoma 
                  ARDS 
                  Maternal death  
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Management protocol for mild preeclampsia27: 
                                       Maternal and fetal evaluation  
 
 
                                       ≥ 37 weeks gestation ( or ) 
                                       ≥ 34 weeks gestation  with 
Labour / Premature rupture of  membranes 
 Abnormal fetal   heart rate                                   Delivery 
 
 
                                                           No (or) 
                 < 34 weeks of gestation 
 Inpatient or outpatient  
 Evaluation and management 
 
 
Worsening of maternal or fetal status  (or) 
                                              Gestation  ≥ 37 weeks 
 
 
                                                        Delivery  
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Management: 
               According to National Institute of Clinical Excellence guidelines 
(NICE , UK) January 2011, patients with blood pressure 150 - 159 / 100- 
109 mmHg are managed as out patients with antihypertensives28. 
               The first line of management is with T.Labetalol to keep systolic 
pressures below 160mm of hg and diastolic pressures between 80 to 100 
mm hg. The alternative antihypertensives are T.Alpha Methyl dopa and 
T.Nifedipine29 .                
                  According to Peter Von Dadelzen, et al in a meta analysis in 
2007 the ideal agent in rural and remote setting must be administered orally, 
must be able to produce smooth reliable reduction of blood pressure with 
rapid onset of action and minimal overshoot. The drug must have 
preferential CNS vascular effect with no maternal or fetal toxicity. Thus  
T.Nifedipine and T.Labetalol will be the ideal drugs. 
The interventional package should include one or two oral 
antihypertensives. The choice lies between T. Nifedipine and T.Labetalol30. 
             According to Marko Folic et al. (2008) , all hypertensive disorders 
in pregnancy have increased maternal and perinatal risks, but the relation 
between benefits and risks associated with antihypertensive agent in 
pregnancy have not been defined. 
             From a wide palette of drugs the most acceptable antihypertensives 
are T. Methyl Dopa, T. Labetalol and T. Nifedipine31. 
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               Now a days T.Methyl dopa is widely replaced by T. Labetalol and 
T. Nifedipine due to its delayed onset of action. 
             Reena Verma et al. (2012) conducted a prospective randomized 
control study on 90 antenatal women with gestational hypertension 
comparing the efficacy, safety and tolerability of T. Labetalol and T.Methyl 
Dopa. 
             In this study it has been proved that T. Labetalol is equally 
efficacious and better tolerated when compared to T. Methyl Dopa. Hence 
T.Labetalol is preferred over T. Methyl Dopa32. 
 T. Labetalol has an added advantage over T. Methyl Dopa as it 
reduces the blood pressure without significantly affecting the cardiac output 
and heart rate. Hence it improves  the uteroplacental blood flow and fetal 
oxygenation. Thus the incidence of hyaline membrane disease is lower with 
T. Labetalol. 
            Tyagi et al. (2013) conducted a prospective study comparing the 
safety, efficacy and fetomaternal outcome of T.Nifedipine and  
T.Methyldopa. A total of 80 antenatal women with preeclampsia were 
included in the study. The management was based on a step wise protocol. 
Antenatal women were screened and risk factors closely monitored. The 
maternal condition was stabilized and the delivery was initiated at the best 
time for both mother and baby. 
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             Nifedipine was more advantageous than Methyldopa as there was 
better and quicker control of  blood pressure. Nifedipine also had longer 
duration of pregnancy, lesser side effects and improved fetal outcomes. 
Nifiedipine showed better action on lipid profile which is critical in 
preeclampsia patients. 
                Nifedipine was better and more effective on maternal and fetal 
outcomes than Methyldopa33. 
                The other advantage of T. Nifedipine was its tocolytic property in 
addition to the antihypertensive effect in preterm patients34. 
             Hence this study was conducted to compare the efficacy and feto 
maternal outcome of T.Labetlol and T.Nifedipine in mild preeclampsia. 
            
Labetalol 35 
         Labetalol hydrochloride is an adrenergic antagonist with selective 
alpha blockade and non selective beta blockade in a single substance. 
Chemical structure: 
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Labetalol hydrochloride chemically contains 2-hydroxy-5-[1-
hydroxy-2-[(1-methyl-3-phenylpropanol)amino)]ethyl benzamide as has the 
above structure. 
The empirical formula for Labetalol hydrochloride is C19H24N2O3· 
HCl with molecular weight of  364.9 . It exists as two diastereoisomeric 
pairs. Dilevolol, R-R’ stereoisomer constitutes 25% of racemic  labetalol. 
Labetalol  is a white or off white water soluble crystalline powder. 
 
Dosage: 
100 mg, 200 mg, 300 mg Tablets are available.  
       
Clinical Pharmacology: 
The ratio of alpha to beta blockade are 1:3 and 1:7 following oral and 
intravenous administration respectively. It is a competitive  α1 and  β 
adrenergic blocker. 
 
Pharmacodynamics: 
The alpha receptor blocking property is demonstrated by attenuation 
of effect of phenylephrine and by cold pressor test. 
The β1 receptor blockade is demonstrated by attenuation of 
tachycardia by isoproterenol or exercise. Β2 receptors blockade is shown by 
attenuation of hypotension by isoproterenol. 
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Both these properties contribute to decrease in blood pressure in 
hypertensive patients. Labetalol produces dose dependent fall in blood 
pressure without causing tachycardia. 
The peak effect of single dose of Labetalol is seen in 2 to 4 hours and 
duration lasts for 8 hours. With twice a day dosing the maximum steady 
state blood pressure response occurs in 24- 72 hours. 
The antihypertensive efficacy of Labetalol has a linear correlation 
with the logarithm of plasma concentration of Labetalol. 
 
Pharmacokinetics36: 
The bioavailability of T. Labetalol is 100% following oral 
administration. The absolute bioavailability is 25% that is the fraction of the 
drug reaching systemic circulation when compared to intravenous Labetalol 
which is 100%. This is due to high first pass metabolism. 
The t ½ of  Labetalol following oral administration is 6-8 hours. In 
patients with impaired hepatic or renal function the elimination half life is 
not altered, but metabolism is diminished. 
Labetalol is metabolized by conjugation to glucuronides. It is 
excreted via urine, bile and faeces. 
Labetalol  has been shown to cross the placental barrier in humans. 
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Contraindications: 
Bronchial asthma 
Overt cardiac failure 
Heart block 
Cardiogenic shock 
Hypersensitivity 
Used with caution in diabetes and liver diseases. 
 
Drug interactions: 
               2-3% of patients taking  Labetalol along with tricyclic 
antidepressants experience tremors. Labetalol blunts the bronchodialator 
effects of β adrenergic agonists hence the dose of bronchodilator has to be 
increased. Cimetidine increases the bioavailability of Labetalol. Digitalis 
along with Labetalol increases the risk of  bradycardia. Labetalol blunts the 
reflux tachycardia produced by nitroglycerine. 
 
 Labetalol in pregnancy37: 
 Teratogenic effects: 
 Belongs to category C approved by FDA. 
 No fetal malformations studied so far. 
 No decrease in uteroplacental blood flow. 
 No evidence of drug related harm to the fetus. 
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 Crosses the placenta and enhance the pulmonary maturity in fetus, 
hence incidence of respiratory distress syndrome is reduced. 
 Some studies have shown association with IUGR but not yet proved. 
 
Labour and delivery: 
Labetalol does not affect the usual course of labour and delivery. 
Lactation: 
           The American academy of paediatrics classifies Labetaol as 
compatible with breast feeding. 0.004% of maternal dose are excreted in 
breast milk .There are no side effects observed in infants. Long term studies 
of  Labetalol are yet to be studied. 
Adverse effects: 
           According to USA therapeutic trial data base for adverse reaction, 
clinical trials were conducted  in patients utilizing various daily dosage of 
oral Labetalol  upto the maximum of 2400 mg. About 2850 patients were 
included in the study.  
The following adverse effects were noted in the descending order: 
Dizziness 
Fatigue 
Nausea 
Vomiting 
Dyspepsia 
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Parasthesia 
Nasal stuffiness 
Edema 
             These complications were increased with daily dosage of  ≥ 900 mg. 
Other complications are: 
        Hypotention, bradycardia, fever, hepatitis, bronchospasm, A-V block, 
allergy, hypoglycemia, agranulocytosis. 
Over dosage: 
        Over dosage causes postural hypotension and bradycardia. Gastric 
lavage and emetics must be given following oral ingestion of Labetalol. 
Atropine for bradycardia, digitalis for heart failure, nor epinephrine for 
hypotension, epinephrine for bronchospasm and diazepam for seizures can 
be given. 
              In severe beta blocker over dose, glucagon 5-10 mg rapid IV can be 
given. Haemodialysis and peritoneal dialysis removes only < 1% of 
Labetalol. 
Dosage: 
                Recommended initial dose is 100mg twice daily. Usual 
maintainance dose is between 200- 400 mg twice daily. Maximum dose is 
2400 mg per day. 
               The drug should be stored between 2o and 30o C. 
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                                                   Nifedipine38 
               Nifedipine  was the first of the dihydropyridine group of calcium 
channel blockers licensed for use. 
               It was first developed by Bayer in 1970 and used as an 
antihypertensive. It had a severe side effect profile of hypotension. Hence 
newer long acting, modified release formulations were developed. 
    
                                
Nifedipine is 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-           
(2-nitrophenyl)-,dimethyl ester. C17H18N2O6 346.33 
 Nifedipine is a yellow crystalline substance, partially soluble in water 
and soluble in ethanol. It has a molecular weight of 346.3. 
Mechanism of action: 
                 Nifedipine is a slow L type calcium channel blocker of calcium 
ion and inhibits the influx of calcium ions into cardiac muscle and smooth 
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muscle. The unique property is that, it does not affect the serum calcium 
concentration. 
Pharmacokinetics: 
                  Nifedipine is rapidly and fully absorbed after oral ingestion. The 
onset starts in 10 minutes and peaks in 30 minutes. Bioavailability increases 
proportionally from dose 10 to 30 mg and then it does not change 
significantly. It is highly protein bound 92- 98%. The half life of Nifedipine 
is 2 hours. It is metabolized in the liver. 80% of Nifedipine and its 
metabolites are eliminated through kidneys. 
                  The protein binding is reduced in renal and hepatic disease. The 
metabolism is affected in hepatic disease. 
 
Pharmacokinetics: 
 L type slow calcium channel  blockers, nifedipine causes negative 
inotropic  effect on heart. It inhibits the calcium influx into smooth muscle 
cells and myometrial cells, there by producing vasodilation and tocolysis. 
As a reflex to vasodilation there is tachycardia. 
L type voltage sensitive calcium channels are present in cardiac and 
smooth muscle, SA and AV node. The channels are located on the surface 
of plasma membrane of these cells. Nifedipine  binds to these cells and 
blocks the entry of calcium ions there by causing relaxation. At therapeutic 
doses, nifedipine does not depress cardiac function. 
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Pregnancy39: 
 Category C drug by FDA. 
         No teratogenicity has been proved in pregnant women till date40. 
         Modified release preparations have good therapeutic effect and better 
side effect profile. The short acting sublingual form has been withdrawn 
from the market due to hypotension. 
       A review by Levin AC et al, the use of nifedipine in antenatal women, 
concluded that apart from being an effective antihypertensive it also reduces 
the risk of cerebral haemorrhage  and end organ damage. Perinatal  effects 
are yet to be established41.  
Dose: 
             10 mg is given initially followed by 20 mg given every 20- 30 
minutes until a maximum dose of 120 mg/day. 
              In a study by Houtzager BA et al, long term effect in children born 
to mothers who were treated with nifidepine during pregnancy were studied. 
There were no abnormalities detected. 
Labour: 
          It acts as a tocolytic at doses ≥ 20 mg. 
Lactation42: 
         Nifedipine has no effect on milk composition. Less than 5% of  
therapeutic dose is seen in breast milk. The American academy of pediatrics 
classifies nifedipine as compatible with breast feeding. 
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Adverse  effects: 
         Sudden hypotension is one of the greatly feared side effects of 
nifedipine. It is most commonly associated with sublingual usage. 
 
             Peripheral edema, dizziness, nausea, headache, weakness, transient 
hypotention, palpitation, nasal and chest congestion, diarrhoea, constipation, 
rigors, muscle cramps are noted. 
  Among these the most common side effects include: 
 Flushing   
 Head ache 
 Chest pain 
Toxicity43: 
        The most important toxicity is direct extension of its therapeutic action. 
Excessive inhibition of calcium influx causes cardiac depression, cardiac 
arrest and heart failure. 
         Patients receiving beta blockers are sensitive to cardio depressant 
effects of calcium channel blockers. Hence both together has to be used with 
caution. 
Other uses44: 
 Angina and Reynauds phenomenon. 
 Supraventicular tachyarrythmias. 
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 Hypertrophic cardiomyopathy. 
 Tocolysis 
 Migraine      
Advantages of Nifedipine45: 
 More potent coronary and peripheral vasodilator 
 Improves arterial compliance 
 Can be used in patients with bronchial asthma and peripheral 
vascular disease 
 No effect on lipid profile, uric acid, glucose metabolism 
 Tolerance does not occur 
Contraindications46: 
 Unstable angina 
 Left ventricular failure 
 Aortic stenosis 
 Obstructive cardiomyopathy 
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OBSERVATIONS  AND  RESULTS 
 
TABLE  1 
 
AGE OF THE PATIENT 
 
 
 
Age Group A Group B Total Statistical inference (n=50) (%) (n=50) (%) (n=100) (%) 
Below 20yrs 4 8.0% 3 6.0% 7 7.0% 
X2=.385 Df=3 
.943>0.05 
Not Significant 
21 to 25yrs 26 52.0% 25 50.0% 51 51.0% 
26 to 30yrs 12 24.0% 12 24.0% 24 24.0% 
31 yrs & 
above 8 16.0% 10 20.0% 18 18.0% 
 
 
 
There was no statistical difference between both groups. 
Hence both groups were comparable. 
 
Most common  in age group in both groups were between 21 and 25 
years. 
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TABLE 2 
 
BMI OF THE PATIENT 
 
 
BMI 
Group A Group B Total Statistical 
inference 
(n=50) (%) (n=50) (%) (n=100) (100%) 
Below 18 7 14.0% 8 16.0% 15 15.0% 
X2=.404 
Df=2 
.817>0.05 
Not Significant 
18 to 24 19 38.0% 16 32.0% 35 35.0% 
Above 25 24 48.0% 26 52.0% 50 50.0% 
 
BMI: 
 
There was no statistical difference between both groups. 
Hence both groups were comparable. 
In both the groups most of the patients were overweight with BMI more 
than 25.  
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TABLE  3 
 
OBSTETRIC SCORE OF THE PATIENT 
 
 
Obstetric 
score 
Group A Group B Total Statistical 
inference (n=50) (%) (n=50) (%) (n=100) (100%) 
G1 26 52.0% 24 48.0% 50 50.0% 
X2=.480 Df=3 
.923>0.05 
Not Significant 
G2 14 28.0% 16 32.0% 30 30.0% 
G3 7 14.0% 8 16.0% 15 15.0% 
G4 3 6.0% 2 4.0% 5 5.0% 
 
 
 
GRAVIDA: 
 
In group A majority 52% were primi gravida. 
In group B majority 48% were primi gravda 
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TABLE 4  
GESTATIONAL AGE AT DIAGNOSIS 
 
 
Gestational age at 
diagnosis (Weeks) 
Group A Group B Total Statistical 
inference (n=50) (%) (n=50) (%) (n=100) (100%) 
28 to 33wks 10 20.0% 10 20.0% 20 20.0% 
X2=.000 
Df=2 
1.000>0.05 
Not 
Significant 
34 to 36wks 30 60.0% 30 60.0% 60 60.0% 
Term 10 20.0% 10 20.0% 20 20.0% 
 
GESTATIONAL AGE: 
 
In group A majority were diagnosed between 34 and 36 weeks. 
In group B majority were diagnosed between`34 and 36 weeks. 
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TABLE 5 
 
REQUIRED DOSE OF THE DRUG –GROUP A 
T.LABETALOL 
 
                            
         
 
 
 
  
 
 
 
 
 
 
 
 
 
 Majority of the patients required dose between 200 and 400 mg. 
Dose (mg) 
Group A 
(n=50) (100%) 
200 17 34.0% 
300 13 26.0% 
400 11 22.0% 
500 7 14.0% 
600 2 4.0% 
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TABLE 6 
 
REQUIRED DOSE OF THE DRUG-GROUP B 
T.NIFEDIPINE 
 
 
Dose (mg) 
Group B 
(n=50) (100%) 
20 14 28.0% 
30 24 48.0% 
40 12 24.0% 
                                         
 Majority of the patients required dose between 20 and 30 mg. 
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TABLE 7 
                               
                            CONTROL OF BLOODPRESSURE 
 
 
Control 
BP 
Group A Group B Total Statistical 
inference 
(n=50) (100%) (n=50) (100%) (n=100) (100%) 
Control 50 100.0% 50 100.0% 100 100.0% Nil 
 
CONTROL OF BLOODPRESSURE: 
 
In group A all 50 patients had adequate control of bloodpressure. 
In group B all 50 patients had adequate control of bloodpressure. 
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TABLE 8 
 
PROGRESSION TO SEVERE PRE ECLAMPSIA 
 
 
Group 
A 
No=50 
% 
Group 
B 
No=50 
% Total % Statistical inference 
Progression 
to severe 
preeclampsia 
 
7 
 
14 
 
10 
 
20 
 
17 
 
17 
X2=0.870 
Df=2 
0.602>0.05 
Not 
significant 
 
 
 
 Among the patients in group A taking Tab.Labetalol 14% 
progressed to  severe preeclampsia. 
                  Among the patients in group B taking Tab...Nifedipine 20% 
progressed to severe preeclampsia. 
                   The difference was not statistically significant. 
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                                          TABLE 9 
     
                        WORSENING OF PROTEINURIA 
 
 
Proteinuria 
>2+ 
Group A Group B Total Statistical 
inference 
(n=50) (%) (n=50) (%) (n=100) (%) 
2+ 1 2.0% 2 4.0% 3 3.0% X2=1.375 
Df=2 
.503>0.05 
Not 
Significant 3+ 0 0% 1 2.0% 1 1.0% 
 
 
 
WORSENING OF PROTEINURIA: 
 
In group A  2% had worsening of proteinuria. They developed urine 
albumin 2+. 
In group  B 6% had worsening of proteinuria. Of which 4% developed urine 
albumin 2+. Remaining 2% developed urine albumin 3+. 
The difference was not statistically significant. 
 
 
 
 
 
 
 
 
 
 59
 
 
 
 
 
 
 
 
CHART 9 
 
WORSENING OF PROTEINURIA 
 
1
2
0
1
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
N
o.
 o
f P
at
ie
nt
s
2+ 3+
Proteinuria
Group A Labetalol Group B Nifedipine
 
 60
 
 
TABLE 10 
 
DEVELOPMENT OF UTERO PLACENTAL INSUFFICIENCY 
 
 
 
IUGR/Oligohy-
dromnios/IUD 
Group A Group B Total Statistical 
inference (n=50) (%) (n=50) (%) (n=100) (%) 
IUGR 1 2.0% 3 6.0% 4 4.0% 
X2=2.244 
Df=3 
.523>0.05 
Not 
Significant 
Utero Placental 
insufficiency 2 4.0% 3 6.0% 5 5.0% 
IUD 1 2.0% 0 .0% 1 1.0% 
 
 
DEVELOPMENT OF UTERO PLACENTAL INSUFFICIENCY: 
 
In group A 2% progressed by developing IUGR . 4% developed 
oligohydramnios. 2% had intrauterine death of the fetus. 
In group B 6% progressed by developing IUGR. 6% developed 
oligohydramnios. 
The difference was not statistically significant. 
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TABLE 11 
DEVELOPMENT OF PAPILLEDEMA 
 
Papilledema 
Group A Group B Total Statistical 
inference (n=50) (%) (n=50) (%) (n=100) (%) 
 1 2.0% 0 .0% 1 1.0% 
X2=1.010 
Df=1.315>0.05 
Not Significant 
 
DEVELOPMENT OF PAPILLEDEMA: 
In group A 2% of the patients developed papilledema. 
In group B none of the patients developed papilledema. 
The difference was not significant. 
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TABLE 12 
 
ONSET OF IMMINENT ECLAMPSIA 
 
 
Imminent 
Eclampsia 
Group A Group B Total Statistical 
inference (n=50) (%) (n=50) (%) (n=100) (%) 
1 1 2.0% 1 2.0% 2 2.0% 
X2=.000 
Df=1 
1.000>0.05 
Not 
Significant 
 
ONSET OF IMMINENT ECLAMPSIA: 
 
In group A and group B 2% of the patients had imminent eclampsia. 
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TABLE 13 
 
DRUG SIDE EFFECTS 
 
Chi-square test 
 
Drug side 
effects 
Group A Group B Total Statistical 
inference (n=50) (%) (n=50) (%) (n=100) (%) 
Giddiness 0 0% 1 2.0% 1 1.0% 
X2=11.383 Df=3 
.049<0.05 
Significant 
palpitation 0 0% 2 4.0% 2 2.0% 
headache 0 0% 3 6.0% 3 3.0% 
 
 
DRUG SIDE EFFECTS: 
 
In group A none of the patients developed drug side effects. 
In group B 12% of the patients had side effects. Of which 6% had headache. 
4% had palpitation and 2% had giddiness. 
There was statistically significant difference between the two groups. 
 Group B had significantly higher side effects than group A. 
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TABLE 14 
 
GESTATIONAL AGE AT DELIVERY 
 
Chi-square test 
Gestational 
age at Delivery 
(Weeks) 
Group A Group B Total Statistical 
inference (n=50) (%) (n=50) (%) (n=100) (%) 
28 to 33wks 3 6.0% 4 8.0% 7 7.0% 
X2=.651 
Df=2 
.722>0.05 
Not 
Significant 
34 to 36wks 4 8.0% 6 12.0% 10 10.0% 
Term 43 86.0% 40 80.0% 83 83.0% 
 
 
 
GESTATIONAL AGE AT DELIVERY: 
 
In group A 86 % delivered at term.  
In group B 80% delivered at term. 
There was no significant difference between the two groups. 
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TABLE 15 
 
                                      MODE OF DELIVERY 
 
Chi-square test 
 Group A Group B Total Statistical inference (n=50) (%) (n=50) (%) (n=100) (%) 
Vaginal 38 76.0% 35 70.0% 73 73.0% 
X2=.464 
Df=2 
.793>0.05 
Not 
Significant 
Emergency 7 14.0% 9 18.0% 16 16.0% 
Elective 5 10.0% 6 12.0% 11 11.0% 
 
 
 
CAESAREAN SECTION: 
 
In group A 24% delivered  by caesarean section. Among them 14% 
emergency section and 10% were taken up as elective section. 
In group B 30% delivered by caesarean section. Among them 18% 
emergency section and 12% were taken up as elective section. 
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TABLE 16 
 
MODE OF DELIVERY 
 
 
                                        VAGINAL DELIVERY 
 
Chi-square test 
 
Vaginal Group A Group B Total Statistical inference (n=50) (%) (n=50) (%) (n=100) (%) 
labour natural 4 8.0% 5 10.0% 9 9.0% 
X2=1.095 
Df=4.895>0.05 
Not Significant 
labour natural 
with 
episiotomy 
28 56.0% 24 48.0% 52 52.0% 
outlet forceps 
delivery 4 8.0% 3 6.0% 7 7.0% 
vacuum 
delivery 2 4.0% 3 6.0% 5 5.0% 
 
 
MODE OF DELIVERY VAGINAL DELIVERY: 
 
In group A 76% patients delivered vaginally. Of which 12% had 
instrumental delivery. 
In group B 70% patients delivered vaginally. Of which 12% had 
instrumental delivery. 
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TABLE  17 
 
NEONATAL OUTCOME 
 
 
Chi-square test 
 Group A Group B Total Statistical inference (n=50) (%) (n=50) (%) (n=100) (%) 
Pre 
term 7 14.0% 10 20.0% 17 17.0% X2=.638 Df=1 
.424>0.05 
Not Significant 
Term 43 86.0% 40 80.0% 83 83.0% 
 
 
NEONATAL OUTCOME: 
 
In group A 43  (86%) were term babies. 
In group B 40 (80%) were term babies. 
In both the groups all term babies had birth weight more than 3 kg. 
There was no statistical difference in the neonatal outcome. 
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TABLE 18 
 
BIRTH WEIGHT OF BABIES 
 
Chi-square test 
Birth 
weight(Kg) 
Group A Group B Total Statistical 
inference (n=50) (%) (n=50) (%) (n=100) (%) 
>2.5kg 43 86.0% 40 80.0% 83 83.0% 
X2=.651 
Df=2 
.722>0.05 
Not 
Significant 
  2 to 
2.5kgs 4 8.0% 6 12.0% 10 10.0% 
 
>2kgs 3 6.0% 4 8.0% 7 7.0% 
 
 
BIRTH WEIGHT OF BABIES: 
 
In group A among the 14% pre term babies delivered 6% had birth weight 
less than 2 kg and the remaining 8% had birth weight between 2 and 2.5 kg. 
In group B among the 20% pre term babies  delivered 8% had birth weight 
less than 2 kg and the remaining 12% had birth weight between  2 and 2.5 
kg. 
In both the groups ,all term babies had birth weight more than 2.5 kg. 
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TABLE  19 
 
NEONATAL ADMISSION 
 
Chi-square test 
 
Neonatal 
admission 
Group A Group B Total 
Statistical 
inference (n=50) (100%) (n=50) (100%) (n=100) (100%) 
Yes 4 8.0% 5 10.0% 9 9.0% 
X2=1.111 
Df=2.132>0.05 
Not Significant 
 
 
NEONATAL ADMISSION: 
 
In group A  4 (8%)  babies born had neonatal admission. 
In group B 5 (10%)  babies born had neonatal admission. 
There was no statistical difference between the two groups. 
 
The most common reasons being RDS and TTN. 
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 TABLE  20 
 
POSTPARTUM  FOLLOW UP 
 
Chi-square test 
 
Post 
natal 
Group A Group B Total 
Statistical 
inference (n=50) (%) (n=50) (%) (n=100) (%) 
Yes 2 4.0% 4 8.0% 6 6.0% 
X2=.709 Df=1 
.400>0.05 
Not Significant 
 
 
POSTPARTUM  FOLLOW UP: 
 
In group A  48 patients (96%) did not require anti hypertensive in their post 
partum period. Remaining  2 patients (4%) required treatment. 
In group B  46 patients (92% )did not require anti hypertensive in their post 
partum period. Remaining  4 patients (8%) required treatment.  
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DISCUSSION 
This study compares the efficacy of two antihypertensives, 
T.Labetalol and T.Nifedipine in mild preeclampsia.The drug side effects 
and feto maternal  outcome were also studied. 
100 patients were included in the study. 50 patients were assigned to 
take  T.Labetalol and 50 patients were assigned to take T.Nifedipine. Both 
groups were similar in age group, BMI and gestational age at diagnosis. 
Age of the patients in both groups were between 21 and 25 years. 
Most of the patients in both groups were over weight with BMI more than 
25. 
          In a study by Kumar S Ganesh et al,( June 2010)  risk factors of  
preeclampsia were studied. In this study the common age group at diagnosis 
was between 21 and 30 years47. Most of the patients in this study also were 
over weight with BMI more than 25. 
Regarding the obstetric score, most of the patients in both groups 
were primi gravida. 
In a study by Prakash et al.(2006) it was proved that preeclampsia 
was common among primi gravida rather than multi gravida. 
 In both the groups, for 60% of the patients, gestational age  at 
diagnosis was between 34 and 36 weeks. 
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In group A, that is patients on T.Labetalol the dose required to 
achieve adequate control of blood pressure  ranged from 200mg upto 600mg 
per day. 34% of  the patients  required  200mg, 26% of the patients required 
300mg, 22% of them required 400mg, 14% required 500mg, 4% required 
600mg. 
 In group B, that is patients on T.Nifedipine the dose required ranged 
from 20mg to 40 mg per day. 28% of the patients were controlled with 
20mg, 48% were controlled with 30mg, 24% were controlled with 40mg.  
In both the  groups adequate control of blood pressure was achieved. 
There by proving that both T.Labetalol and T.Nifedipine are equally 
efficacious. 
This result is consistent with a meta analysis by Prof.Peter Von 
Dadelszen et al.(2007). Here the efficacy of oral labetalol and nifedipine 
were analysed in mild preeclampsia. They have proved that both the drugs 
are effective, safe and rapid in their onset of action. 
This is also consistent with the study by Bharathi et al.(2009)48. Here 
antihypertensive efficacy in mild preeclampsia  was studied and it was 
proved that both T.Labetalol and T.Nifedipine are equally effective. 
In contrary to this study, Patel NK et al. (2012 Dec)49 have proved 
that T.Labetalol has better efficacy than T.Nifedipine in mild preeclampsia. 
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Even though adequate control of blood pressure was achieved in both 
the groups the basic pathology behind the disease could not be altered. This 
is evident because in both the groups few patients progressed to severe 
preeclampsia with adequate blood pressure control.  
In group A patients (T.Labetalol)  14% progressed to severe  
preeclampsia. Among them 2% had worsening of protienuria, 8% had utero 
placental insufficieny which was evident by the onset of  oligohydramnios 
(4%) , IUGR (2%) and intrauterine death of the fetus (2%) , 2% developed 
papilledema and 2% developed imminent eclampsia. 
In group B patients (T.Nifedipine) 20% progressed to severe  
preeclampsia. Among them 6% had worsening of proteinuria, 6% had 
oligohydramnios, 6% had IUGR and remaining 2% of them developed 
imminent symptoms. 
Thus even though the rate of disease progression to severe  
preeclampsia was higher in group B , it was not statistically significant. 
Regarding the drug side effects , in group A patients who took 
T.Labetalol none of them developed any side effects. In group B patients 
who took T.Nifedipine 12% of them developed side effects.  
This difference was statistically significant. The most common side 
effect being headache (6%) followed by palpitation (4%) and giddiness 
(2%). Thus proving that T.Labetalol was well tolerated and without any side 
effects. 
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 In the same study by Bharathi et al. both drugs had side effects but 
the side effects were higher in T.Nifedipine group .Similar  to our study the 
most common side effect with T.Nifedipine was headache .But in contrary 
to this study ,where there was no side effects with T.Labetalol ,in the study 
by Bharathi et al. the most common side effect with T.Labetaolol was    
headache . 
In group A patients taking T.Labetalol 86% of them delivered at term 
gestation. Rest of the 14% delivered preterm as pregnancy was terminated 
due to progression to severe preeclampsia, among which 8% delivered 
between 28 and 33 weeks gestation and the rest 6% were between 34 and 37 
weeks gestation. 
 In group B patients taking T.Nifedipine 80% of them delivered at 
term gestation. Rest of the 20% delivered preterm as pregnancy was 
terminated due to progression to severe preeclampsia. Among which 8% 
delivered between 28 and 33 weeks gestation and 12% delivered between 34 
and 37 weeks. 
 Thus in both the groups majority delivered at term. There was no 
significant difference in the gestational age at delivery between both the 
groups.   
In group A patients ,76% had vaginal delivery and 24% had caesarean 
section.In group B patients, 70% had vaginal delivery and 30% had 
caesarean section. 
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    Regarding the neonatal out come , in group A 86% were term 
babies and 14% were preterm babies. Among the 14% , 8% had birth weight 
between 2 and 2.5 kg. The remaining 6% had birth weight less than 2 kg. 
   In group B 80% were term babies and 20% were preterm babies. 
Among the 20%, 12% had birth weight between 2 and 2.5 kg. The remains 
8% had birth weight less than 2 kg.  
     In group A 8% of the babies were admitted in SNN ward and in 
group B 10% of the babies were admitted in SNN ward. The most common 
reason being respiratory distress of new born due to pre maturity. Thus in 
both the groups there is no significant difference in the neonatal outcome. 
     This is consistent with the results of study by E.J.Waterman et al 
(2004)50, which showed that there are no differential effects on utero 
placental or fetal hemodynamics with the use of T.Labetalol and 
T.Nifedipine in hypertension in pregnancy. The same study proved no 
differential effects on neonatal outcome including birth weight. 
      In contrary to this, the study by Patel NK et al.(2012 the neonatal 
outcome was better with T.Labetalol as there was lower incidence of 
respiratory distress of new born. This is because T.Labetalol maintains 
adequate placental perfusion and there by tissue oxygenation. 
     Post partum follow of patients in both the groups , 4% patients in 
group A (T.Labetalol) and 6% patients in group B (T.Nifedipine) required 
continuation of antihypertensive in the post partum period. 
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    In this study none of the patients developed life threatening 
complication of preeclampsia such as coagulopathy, eclampsia, pulmonary 
edema, HELLP syndrome and postpartum colapse. There was no maternal 
mortality in this study. 
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SUMMARY 
                This study was conducted on a total of 100 antenatal  mild 
preeclamptic  women to compare the anti hypertensive efficacy of 
T.Labetalol and T.Nifedipine. The maternal and fetal outcome were also 
studied.  
                Hypertensive disorder in pregnancy  is the third most common 
cause of maternal mortality. Among them 50% of the deaths are preventable 
when diagnosed and treated at an earlier stage. Hence this study was 
proceeded. 
                 Patients were divided into two groups 50 each. Group A received 
T.Labetalol and group B received T.Nifedipine.  
                Blood pressure and feto maternal status were serially monitored. 
Termination was done at 37 completed weeks gestation or when the patient 
progressed to severe  preeclampsia. 
               The average dose required for T.Labetalol was 300 mg and 30 mg 
for T.Nifedipine. 
                In both the groups, all 50 patients had adequate control of blood 
pressure. Inspite of adequate control the disease progressed in both groups.  
                In group A (T.Labetalol) 14% progressed to severe pre eclampsia. 
In group B (T.Nifedipine) 20% progressed to severe pre eclampsia.  
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                Among the babies delivered, in group A 86% were term babies 
and 8% required SNN admission. In group B 80% were term babies and 
10% required SNN admission. 
              Comparing the two groups, group B had significantly higher 
number of side effects when compared to group A. 
               None of the patients developed grave complications such as 
HELLP syndrome ,pulmonary edema, coagulopathy, postpartum collapse, 
eclampsia. The maternal mortality was nil. 
              Thus when patients with preeclampsia are identified and treated at 
an earlier stage the morbidity and mortality associated with preeclampsia 
can be significantly reduced. 
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CONCLUSION 
 
               From this study it is prudent that both T.Labetalol and 
T.Nifedipine are equally efficacious in the control of hypertension in mild 
preeclampsia. 
                In both the groups , there was progression to severe preeclampsia 
in an average of 16% of the patients even though their blood pressure was 
under control. There by showing that the pathology of disease was not 
altered significantly in both the groups. 
              Regarding the drug side effects and tolerability, T.Labetalol was 
significantly better than T.Nifedipine. 
               There was no significant difference in the neonatal outcome 
between the two groups. 
               Thus T.Labetalol is a better alternative to T.Nifedipine, as it 
had lesser side effect profile. 
                But in a limited resource setting, T.Nifedipine is an equally 
effective, cheap and easily available drug for mild preeclampsia. 
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PROFORMA 
NAME:                                                            ADDRESS: 
AGE: 
IP NUMBER: 
PHONE NUMBER:                                         HT:                              WT:  
OBSTETRIC SCORE:                                     LMP:                           EDD: 
GESTATIONAL AGE AT DIAGNOSIS: 
BP ON ADMISSION: 
PRESENTING ILLNESS:                                           
PAST H/O: 
MENSTRUAL H/O:                                             MARITAL H/O: 
RISK FACTORS: 
INVESTIGATIONS: 
CT: 
CRT: 
 RFT:SR.UREA:                     CREATININE:                          RBS: 
LFT:TOTAL BILIRUBIN:              DIRECT:                   INDIRECT: 
SGOT:                            SGPT: 
CBC:HB:                         PLATELET: 
PROTHROMBIN TIME: 
URINE ALBUMIN: 
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 URINE SUGAR:  
                    
URINE DEPOSITS: 
 
FUNDUS OPINION: 
 
ULTRASOUND FINDING: 
 
DRUG: 
 
DOSE: 
 
MODIFIED BIOPHYSICAL PROFILE: 
 
GESTATIONAL AGE AT TERMINATION: 
 
REASON FOR TERMINATION: 
 
COMPLICATIONS: 
 
Maternal 
 
Drug induced 
 
MODE OF DELIVERY: 
 
NEONATAL OUTCOME: 
 
NEONATAL ADMISSIONS: 
 
DURATION OF STAY IN NICU 
: 
POST PARTUM FOLLOW UP: 
 
 
 
 96
 97
 98
 99
 100
 101
 102
 103
 
 104
 
ABBREVATION 
BP   - Blood Pressure 
T.Labetalol  - Tablet Labetalol 
T.Nifedipine  - Tablet Nifedipine 
T.Methyl Dopa  -Tablet Methyl Dopa 
FDA   - Food and Drug Association 
IUGR   - Intra Uterine Growth Retardation 
IUD   -Intra Uterine Death 
HELLP   - Hemolysis Elevated Liver Enzymes and Low Platelet
A-V Block  - Atrio Ventricular Block 
IV    - Intra Venous 
BMI   - Body Mass Index 
SNN   - Sick Neo Nate  
OPD   -Out Patient Department 
MSAFP   - Maternal Serum Alpha Feto Protein 
HCG   -Human Chorionic Gonadotrophin 
MDA   -MalonDiAldehyde 
CNS   -Central Nervous System 
RDS   -Respiratory Distress Syndrome 
TTN   -Transient Tachypnoea of Newborn 
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                                               ABSTRACT 
Aim: 
       To compare the anti hypertensive efficacy of T. Labetalol and T.Nifedipine 
in mild preeclampsia and to study its feto maternal outcome.                                                                                      
Methodology: 
             Totally 100 antenatal women with mild preeclampsia were included in 
the study. 50 were started on T.Labetalol (Group A) and 50 were started on 
T.Nifedipine (Group B).  Blood pressure, disease progression, drug side effects 
and neonatal outcome were monitored. Termination was done at 37 completed 
weeks gestation or when the patient progressed to severe preeclampsia. 
Results: 
               The average dose required for control of blood pressure with 
T.Labetalol was 300 mg and 30 mg for T.Nifedipine. 
                In both the groups, all 50 patients had adequate control of blood 
pressure. Inspite of adequate control the disease progressed in both groups. In 
group A (T.Labetalol) 14% progressed to severe preeclampsia. In group B 
(T.Nifedipine) 20% progressed to severe preeclampsia.  
                Among the babies delivered, in group A 86% were term babies and 
8% required SNN admission. In group B 80% were term babies and 10% 
required SNN admission. 
              Comparing the two groups, group B (T.Nifedipine) had significantly 
higher number of side effects when compared to group A (T.Labetalol) . 
               None of the patients developed grave complications such as HELLP 
syndrome, pulmonary edema, coagulopathy, postpartum collapse, eclampsia. 
The maternal mortality was nil. 
              Thus when patients with preeclampsia are identified and treated at an 
earlier stage the morbidity and mortality associated with preeclampsia can be 
significantly reduced. 
Conclusion: 
               T.Labetalol is a better alternative to T.Nifedipine, as it had lesser side 
effect profile. 
                But in a limited resource setting, T.Nifedipine is an equally effective, 
cheap and easily available drug for mild preeclampsia. 
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